Literature DB >> 25377442

Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population.

D Nugent1, W Kalnins, F Querol, M Gregory, T Pilgaard, D L Cooper, A Iorio.   

Abstract

The HERO (Haemophilia Experiences, Results and Opportunities) quantitative surveys collected information on characteristics and perceptions of adult persons with haemophilia (PWH) and parents of children with haemophilia. The aim of this article is to describe the perceptions of PWH and parents on psychosocial aspects related to treatment. Two online surveys (one for PWH, one for parents) were conducted in 10 countries. Among 675 PWH respondents, 77% reported having responsibility for their own care; 72% of 561 parent respondents had the main responsibility for their son. PWH were most commonly treated on demand (45% of 648 adults using factor concentrate), with 32% on regular prophylaxis and 23% treated on demand with short-term prophylaxis (e.g. for sports/physiotherapy). Children were most often treated with prophylaxis (65% of 549 children using factor concentrate), with 26% treated on demand and 8% treated on demand with short-term prophylaxis. Factor was generally used as instructed at home. Some respondents (41% PWH; 30% parents) had difficulties/concerns with factor availability/affordability. PWH reported more bleeds in the last 12 months than parents reporting their son's bleeds (mean 17.8 vs. 8.7). Both PWH and parents generally perceived that overall, their (their son's) haemophilia was well controlled. Results differed by country. The HERO study captured new, patient-based data regarding many facets of life relevant to PWH, including treatment. The information conveyed in this article largely represents new insights regarding perceptions of treatment and provides initial benchmark statistics for further research.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  access; comprehensive care; haemophilia; psychosocial; treatment

Mesh:

Year:  2014        PMID: 25377442     DOI: 10.1111/hae.12545

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  6 in total

1.  Predictors of quality of life among adolescents and young adults with a bleeding disorder.

Authors:  John M McLaughlin; James E Munn; Terry L Anderson; Angela Lambing; Bartholomew Tortella; Michelle L Witkop
Journal:  Health Qual Life Outcomes       Date:  2017-04-07       Impact factor: 3.186

Review 2.  Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic.

Authors:  Shilpa Jain; Jennifer Donkin; Mary-Jane Frey; Skye Peltier; Sriya Gunawardena; David L Cooper
Journal:  J Blood Med       Date:  2018-11-19

3.  Health care professionals dealing with hemophilia: insights from the international qualitative study of the HERO initiative.

Authors:  Silvia Potì; Laura Palareti; Frederica Rmy Cassis; Sonia Brondi
Journal:  J Multidiscip Healthc       Date:  2019-05-09

Review 4.  The existing scenario of haemophilia care in Canada and China - A review.

Authors:  Rohan Pratap; Monali Misra; Varun N; Suman Morampudi; Anand Patil; Jayachandra Reddy
Journal:  Hematol Transfus Cell Ther       Date:  2019-10-27

5.  The impact of improving haemophilia A management within the Spanish National Healthcare System: a social return on investment analysis.

Authors:  Inmaculada Soto; José Mateo; Daniel-Aníbal García-Diego; Beatriz Gil; Elena Ruiz-Beato; Yoana Ivanova; Teresa Martín Lorenzo; Paulina Maravilla-Herrera; Álvaro Hidalgo-Vega; María Merino
Journal:  BMC Health Serv Res       Date:  2022-01-26       Impact factor: 2.655

6.  Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study.

Authors:  Angela L Forsyth; Michelle Witkop; Angela Lambing; Cesar Garrido; Spencer Dunn; David L Cooper; Diane J Nugent
Journal:  Patient Prefer Adherence       Date:  2015-10-29       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.